<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="146">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002744</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia</studytitle>
    <scientifictitle>Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CCG-1952</secondaryid>
    <secondaryid>1952</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - asparaginase
Treatment: drugs - cyclophosphamide
Treatment: drugs - cytarabine
Treatment: drugs - daunorubicin hydrochloride
Treatment: drugs - dexamethasone
Treatment: drugs - doxorubicin hydrochloride
Treatment: drugs - mercaptopurine
Treatment: drugs - methotrexate
Treatment: drugs - pegaspargase
Treatment: drugs - prednisone
Treatment: drugs - therapeutic hydrocortisone
Treatment: drugs - thioguanine
Treatment: drugs - vincristine sulfate
Treatment: other - low-LET cobalt-60 gamma ray therapy
Treatment: other - low-LET photon therapy

Experimental: Arm I - Therapy defined in description.

Experimental: Arm 2 - Therapy defined in description.

Experimental: Arm 3 - Therapy defined in description.

Experimental: Arm 4 - Therapy defined in description.


Treatment: drugs: asparaginase


Treatment: drugs: cyclophosphamide


Treatment: drugs: cytarabine


Treatment: drugs: daunorubicin hydrochloride


Treatment: drugs: dexamethasone


Treatment: drugs: doxorubicin hydrochloride


Treatment: drugs: mercaptopurine


Treatment: drugs: methotrexate


Treatment: drugs: pegaspargase


Treatment: drugs: prednisone


Treatment: drugs: therapeutic hydrocortisone


Treatment: drugs: thioguanine


Treatment: drugs: vincristine sulfate


Treatment: other: low-LET cobalt-60 gamma ray therapy


Treatment: other: low-LET photon therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Event Free Survival - Primary outcome index used in examining the randomized treatment groups will be event-free survival (EFS) from the time of randomization (i.e., end of Induction), where the life table events will consist of the first occurrence of leukemic relapse at any site, death, or occurrence of a second malignancy.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparisons of CNS relapse incidence rates - Comparisons of CNS relapse incidence rates for the IT MTX versus ITT groups is also planned as an important endpoint.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Newly diagnosed acute lymphoblastic leukemia (ALL) obtained by
        bone marrow aspirate or bone marrow biopsy No greater than 25% L3 blasts Initial white
        blood cell count less than 50,000/mm3 (performed at CCG institution) Massive
        lymphadenopathy, massive splenomegaly, and/or large mediastinal mass allowed CNS or
        testicular leukemia allowed Allogeneic bone marrow transplant should be considered (if
        donor available) for patients with Philadelphia chromosome (t[9;22][q34;q11]) or
        translocation (4;11)(q21;q23)

        PATIENT CHARACTERISTICS: Age: 1 through 9 Performance status: Not specified Hematopoietic:
        See Disease Characteristics Hepatic: Not specified Renal: Not specified

        PRIOR CONCURRENT THERAPY: No prior treatment for ALL Biologic therapy: Not specified
        Chemotherapy: Intrathecal cytarabine (IT ARA-C) may begin prior to registration provided
        systemic chemotherapy initiated within 72 hours after IT ARA-C Endocrine therapy: See
        Radiotherapy At least 1 month since prior systemic steroids Steroids given for less than 48
        hours allowed Inhaled corticosteroids allowed at any time Radiotherapy: Radiotherapy or
        dexamethasone for mediastinal mass causing superior mediastinal syndrome allowed prior to
        registration, if indicated Surgery: Not specified</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>9</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/1996</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1970</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug and giving them in different ways
      may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is
      more effective for acute lymphoblastic leukemia

      PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy
      in treating children who have newly diagnosed acute lymphoblastic leukemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002744</trialwebsite>
    <publication>Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008 Dec;22(12):2142-50. doi: 10.1038/leu.2008.251. Epub 2008 Sep 25.
Matloub Y, Asselin BL, Stork LC, et al.: Outcome of children with T-Cell acute lymphoblastic leukemia (T-ALL) and standard risk (SR) features: results of CCG-1952, CCG-1991 and POG 9404. [Abstract] Blood 104 (11): A-680, 195a, 2004.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Linda C. Stork, MD</name>
      <address>Doernbecher Children's Hospital at Oregon Health and Science University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>